In an era of cancer immunotherapies, the recent introduction of neoantigen cancer vaccine (also referred neovaccines) has garnered new hope in the medical community, owing to their ability to induce the body’s natural defenses against abnormal malignancies. Cancer is very complex to treat. Sometimes target antigens are also present on normal cells and cancerous cells, making the body vulnerable to attacks in the wrong places by the current mainstays of immunotherapies. Ironically, this phenomenon provides an opportunity for neoantigen cancer vaccine to step in and fill up the potential treatment gaps by selectively targeting cancerassociated antigens. Neoantigens are foreign peptides that are totally absent from the normal healthy cells and are specifically identified by neoantigen-specific T-cell receptors in terms of major histocompatibility complexes (MHCs) molecules. Unlike the tumor-associated antigens and cancer germline antigens, normally present on cancer and healthy cells, neoantigens are exclusively present on the tumor tissues and thus provide an initial concept of targeting them.

1. Product Definition 

2. Research Scope 

3. Research Methodology 

4. Neoantigen Cancer Vaccine in Cancer Immunotherapy Overview

5. Industry Insights

6. Impact of COVID-19 on the Global Neoantigen Cancer Vaccine Market 

7. Market Dynamics

8. Pipeline Landscape